Placebo-controlled study in neuromyelitis optica-Ethical and design considerations (Q36996492)

17 August 2017

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations (English)

1 reference

17 August 2017

0 references

0 references

Hans-Peter Hartung

1 reference

17 August 2017

Gary Cutter

0 references

Brian G Weinshenker

object named as

Brian Weinshenker

1 reference

17 August 2017

Friedemann Paul

1 reference

17 August 2017

Dean Wingerchuk

1 reference

17 August 2017

Kazuo Fujihara

1 reference

17 August 2017

Sean Pittock

1 reference

17 August 2017

Bruce Ac Cree

1 reference

17 August 2017

Jeffrey L Bennett

1 reference

17 August 2017

Mark Sheehan

1 reference

17 August 2017

Jeffrey Cohen

1 reference

17 August 2017

Orhan Aktas

1 reference

17 August 2017

Ho Jin Kim

1 reference

17 August 2017

Kaushik Patra

1 reference

17 August 2017

Armando Flor

1 reference

17 August 2017

Gerard Barron

1 reference

17 August 2017

Soraya Madani

1 reference

17 August 2017

John N Ratchford

1 reference

17 August 2017

Eliezer Katz

1 reference

17 August 2017

language of work or name

1 reference

14 December 2015

1 reference

Multiple Sclerosis Journal

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

862-872

1 reference

Placebo controlled trials in neuromyelitis optica are needed and ethical

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Demographic and clinical features of neuromyelitis optica: A review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Challenges and opportunities in designing clinical trials for neuromyelitis optica

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Treatment of Neuromyelitis Optica: Review and Recommendations.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

The incidence and prevalence of neuromyelitis optica: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Statistical cures and other fallacies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

EFNS guidelines on diagnosis and management of neuromyelitis optica

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Revised diagnostic criteria for neuromyelitis optica

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Systematic reviews: synthesis of best evidence for clinical decisions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Integrating Heterogeneous Pieces of Evidence in Systematic Reviews

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Levels of evidence: Taking Neurology to the next level.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904355

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1352458515620934

Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary

21 January 2018

1 reference

12 December 2020

Placebo studies should not be undertaken in NMO--No

1 reference

12 December 2020

Placebo studies should not be undertaken in NMO--Yes

1 reference

12 December 2020

Impact of rituximab on relapse rate and disability in neuromyelitis optica

1 reference

12 December 2020

Identifiers

DOI

10.1177/1352458515620934

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

26666258

1 reference